Valproic acid and nonalcoholic fatty liver disease: A possible association?
作者： Edoardo Farinelli , David Giampaoli , Anja Cenciarini , Ephraim Cercado , Alberto Verrotti
关键词:
摘要: Valproic acid (VPA) is one of the most prescribed drugs in children with newly diagnosed epilepsy. Weight gain and obesity have been observed as side effects VPA. These are often linked other metabolic disturbances such development insulin resistance, dyslipidemia, syndrome (MetS) non-alcoholic fatty liver disease or nonalcoholic (NAFLD). NAFLD refers to a group disorders marked hepatic steatosis. It associated an increased incidence cardiovascular diseases overall reduced life expectancy. occurs 20%-25% general population it known be common cause chronic disease. therefore represents major public health issue worldwide. This study reviews summarizes relevant literature that supports existence association between VPA therapy children. Long-term VPA-therapy appears risk developing NAFLD. Further studies needed clarify pathogenic mechanisms lie behind this standardize options for use drug overweight patients those risks MetS
sci-hub.se 参考文章(50)
Emilio Perucca, Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. ,vol. 16, pp. 695- 714 ,(2002) , 10.2165/00023210-200216100-00004
Paola Loria, Luigi Elio Adinolfi, S Bellentani, Elisabetta Bugianesi, Alessandro Grieco, S Fargion, Antonio Gasbarrini, Carmelina Loguercio, A Lonardo, G Marchesini, Fabio Marra, Marcello Persico, D Prati, Gianluca Svegliati-Baroni, NAFLD Expert Committee of the Associazione Italiana per lo Studio del Fegato, None, Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Digestive and Liver Disease. ,vol. 42, pp. 272- 282 ,(2010) , 10.1016/J.DLD.2010.01.021
A. Verrotti, C. D'Egidio, A. Mohn, G. Coppola, F. Chiarelli, Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obesity Reviews. ,vol. 12, pp. 32- 43 ,(2011) , 10.1111/J.1467-789X.2010.00800.X
Yuguang Shi, Jamil Kanaani, Virginie Menard-Rose, Yan Hui Ma, Pi-Yun Chang, Douglas Hanahan, Allan Tobin, Gerold Grodsky, Steinunn Baekkeskov, Increased expression of GAD65 and GABA in pancreatic β-cells impairs first-phase insulin secretion American Journal of Physiology-endocrinology and Metabolism. ,vol. 279, ,(2000) , 10.1152/AJPENDO.2000.279.3.E684
R.B. Meeker, R.D. Myers, GABA and glutamate: Possible metabolic intermediaries involved in the hypothalamic regulation of food intake Brain Research Bulletin. ,vol. 5, pp. 253- 259 ,(1979) , 10.1016/0361-9230(80)90042-8
James H. Lewis, Hyman J. Zimmerman, Carlton T. Garrett, Elliot Rosenberg, Valproate-induced hepatic steatogenesis in rats. Hepatology. ,vol. 2, pp. 870- 873 ,(1982) , 10.1002/HEP.1840020622
Valerio Nobili, Gianluca Svegliati-Baroni, Anna Alisi, Luca Miele, Luca Valenti, Pietro Vajro, A 360-degree overview of paediatric NAFLD: recent insights. Journal of Hepatology. ,vol. 58, pp. 1218- 1229 ,(2013) , 10.1016/J.JHEP.2012.12.003
Russell Brown, Syed A. Imran, Ehud Ur, Michael Wilkinson, Valproic Acid and CEBPα-Mediated Regulation of Adipokine Gene Expression in Hypothalamic Neurons and 3T3-L1 Adipocytes Neuroendocrinology. ,vol. 88, pp. 25- 34 ,(2008) , 10.1159/000113927
R. Greco, G. Latini, F. Chiarelli, P. Iannetti, A. Verrotti, Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. ,vol. 65, pp. 1808- 1809 ,(2005) , 10.1212/01.WNL.0000187074.27586.D1
Jiajia Fang, Sihan Chen, Nanwei Tong, Lan Chen, Dongmei An, Jie Mu, Dong Zhou, Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure-european Journal of Epilepsy. ,vol. 21, pp. 578- 582 ,(2012) , 10.1016/J.SEIZURE.2012.06.001